Trials / Unknown
UnknownNCT01195298
Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- South Eastern European Research Oncology Group · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine and Bevacizumab | Drugs will be administered in 3-week cycles as follows: * Bevacizumab 15mg/kg via i.v. infusion on day 1 * Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-08-01
- First posted
- 2010-09-06
- Last updated
- 2010-09-06
Locations
1 site across 1 country: Croatia
Source: ClinicalTrials.gov record NCT01195298. Inclusion in this directory is not an endorsement.